AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06592261
Drug: Glucagon, 0-0.5 ng/kg/min
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Replacement of endogenous glucagon suppressed by octreotide. (Use is optional at the PI's discretion.)
Trial: NCT06735079
Drug: REL1017 (esmethadone HCI) (active drug)
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REL-1017 is an investigational drug administered as an oral tablet, once daily. The dosing regimen includes a 75 mg dose on Day 1 (three tablets) in the clinic, followed by 25 mg daily (one tablet) at home from Day 2 to Day 28, with regular safety, efficacy, and tolerability assessments REL-1017 (esmethadone HCl) is under investigation as a novel NMDAR antagonist. Unlike racemic methadone, it lacks opioid-like effects such as dependency or respiratory depression. REL-1017 also lacks dissociative effects seen with more potent NMDAR antagonists such as ketamine. Finally, REL-1017 does not appear to have metabolic or neurological side effects.
Trial: NCT06735703
Drug: To provide ampicillin sulbactam to pregnant women with premature rupture of membrane
RxNorm normalized name: ampicillin / sulbactam
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To provide ampicillin sulbactam tonpregnant women with premature rupture of membrane after 34 wks gestation
Trial: NCT06735235
Drug: 0 ppm F
RxNorm normalized name: Sodium Fluoride 6 mg in 1 mL DENTAL PASTE, DENTIFRICE [Sodium Fluoride 5000 ppm Fruit]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Trial: NCT05846789
Drug: SOC Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
Trial: NCT05846789
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks
Trial: NCT04739761
Drug: Trastuzumab Deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive T-DXd administered using an IV bag containing 5% (w/v) dextrose injection infusion solution.
Trial: NCT06732388
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06738745
Drug: HRS-2189
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-2189
Trial: NCT06738745
Drug: HRS-5041
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-5041
Trial: NCT06740149
Drug: Bone marrow mesenchymal stem cells (low dose)
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously. For phase I: single infusion, 1.0×10\^6 cells/kg. For phase II: 1.0×10\^6 cells /kg once a week for a total of 4 times.
Trial: NCT06740149
Drug: Solvent of CG-BM1
RxNorm normalized name: CG-200745
DrugBank: CG-200745 (DB12259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously, once a week for a total of 4 doses.
Trial: NCT06740149
Drug: Bone marrow mesenchymal stem cells (medium dose)
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously. For phase I: single infusion, 2.0×10\^6 cells /kg. For phase II: 2.0×10\^6 cells /kg once a week for a total of 4 times.
Trial: NCT06740149
Drug: Bone marrow mesenchymal stem cells (high dose)
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously. For phase I: single infusion, 4×10\^6 cells /kg.
Trial: NCT06737549
Drug: Nerver growth factor (NGF) injection
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 20ug mouse nerve growth factor (NO. S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd., Wuhan, China. mNGF will be dissolved in 2 ml of sterile water for injection and then injected intramuscularly into the gluteal muscle, three times a week for 6 weeks.
Trial: NCT06093438
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this arm would receive three cycles of induction treatment before receiving definitive chemoradiotherapy. The specific regimen is: Paclitaxel(135mg/m2,ivd, d1)+cisplatin(75mg/m2,ivd,d1-3)+Toripalimab (240mg,ivd,d1)±bevacizumab(ivd, d1)/q21d. Patients would receive pelvic MRI to evaluate the regression status of tumor after three cycles of induction treatment. Patients with satisfying tumor regression would receive definitive chemoradiotherapy afterwards. During chemoradiotherapy, patients would receive weekly cisplatin (40mg/m2) and 240mg toripalimab every three weeks. After chemoradiotherapy, patients would receive another three cycles of consolidated treatment (regimen identical to induction treatment).
Trial: NCT05371613
Drug: tividenofusp alfa
RxNorm normalized name: Tividenofusp alfa
DrugBank: Tividenofusp alfa (DB17628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT05371613
Drug: idursulfase
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT04629547
Drug: Suvorexant 20 mg
RxNorm normalized name: suvorexant 20 MG
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suvorexant 20mg will be taken nightly for 24 months.
Trial: NCT06742554
Drug: Buprenorphine transdermal patch
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine Transdermal Patch (10 mg): Applied once before surgery for continuous pain control.~Interscalene Brachial Plexus Block: Administered intraoperatively using 25 mL of 0.5% bupivacaine.
Trial: NCT06742554
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol: Administered orally or intravenously at a standard dose of 100 mg every 8 hours, based on patient-reported pain levels.~Interscalene Brachial Plexus Block: Administered intraoperatively using 25 mL of 0.5% bupivacaine.
Trial: NCT04944524
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Tofacitinib 5mg twice a day for 12months;~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization.
Trial: NCT05047952
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants aged 18-64 years receiving vortioxetine will be provided 10 mg/day on days 1-14 of the treatment period, and will be titrated to 20 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 20 mg/day, unless adjudicated otherwise by a study clinician.~Per product monograph, participants aged 65+ years receiving vortioxetine will be provided 5 mg/day on days 1-14 of the treatment period, and will be titrated to 10 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 10 mg/day, unless adjudicated otherwise by a study clinician.
Trial: NCT05903859
Drug: Probenecid 500 Milligrams (mg)
RxNorm normalized name: probenecid 500 MG
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this group will receive 500 mg of probenecid by mouth twice a day for a total of 90 days.
Trial: NCT05903859
Drug: probenecid 250 Milligrams (mg)
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this group will receive 250 mg of probenecid by mouth twice a day for a total of 90 days.
Trial: NCT06745492
Drug: Neostigmine + Glycopyrrolate
RxNorm normalized name: glycopyrrolate / neostigmine Injectable Solution
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a 20 mcg/kg of neostigmine and 4 mcg/kg of glycopyrrolate were administered at a TOF ratio of 0.7.
Trial: NCT06121882
Drug: Saline Injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-articular knee injection of saline
Trial: NCT06743802
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 was administered from admission to one month after discharge at a dose of 200 mg per day (200 mg/qd).
Trial: NCT06745804
Drug: 68Ga-R10602 injection
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-R10602 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions in hormone receptor positive breast cancer
Trial: NCT06743919
Drug: Magnesium sulfate 50% - 1g/h
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: magnesium sulfate group 20 ml bupivacaine 0.25% plus 500 mg magnesium sulfate in 5ml normal saline on both sides.
Trial: NCT06743919
Drug: dexmedetomidine 0.5 µg/kg IV
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine group 20 ml bupivacaine 0.25% plus o .5 microg per kg dexmedetomidine in 5 ml normal saline on both sides.
Trial: NCT06743919
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml bupivacaine 0.25% plus 5 ml normal saline on both sides.
Trial: NCT05720442
Drug: Tangweian Recipe
RxNorm normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Tangweian recipe is a combination of several Chinese herbs
Trial: NCT05720442
Drug: Mosapride Citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The mosapride citrate tablets will be administrated.
Trial: NCT06745219
Drug: herombopag
RxNorm normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive harombopag for the prevention of thrombocytopenia in the next cycle of chemotherapy
Trial: NCT04658420
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individuals in the ketamine group will receive ketamine 0.5 mg/kg infused over 40 minutes
Trial: NCT06745206
Drug: Lyophilized Recombinant Human Brain Natriuretic Peptide
RxNorm normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to rh-BNP administration, measure: PiCCO indices, hemodynamic parameters, venous return, tissue perfusion, echocardiographic parameters, ultrasound indices, 2-hour averaged urine output and fluid balance. Repeat all above-mentioned measurements at 30 minutes post-initiation.
Trial: NCT06732180
Drug: GT-02287
RxNorm normalized name: GTS-21
DrugBank: GTS-21 (DB05708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent
Trial: NCT06726811
Drug: Droperidol injection
RxNorm normalized name: Droperidol Injection
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg
Trial: NCT05097248
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
Trial: NCT05097248
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan will be orally administered at 50 mg for three days and increased to 100 mg if tolerated until the whole course of chemotherapy; if not tolerated, it will be maintained at 50 mg until the whole course of chemotherapy
Trial: NCT06730672
Drug: Volonib combined with Everolimus Formation
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Volonib 200mg once daily and Everolimus 5mg once daily
Trial: NCT06729996
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take 30 mg tablet, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 45 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food till 24 weeks.
Trial: NCT06729996
Drug: Empagliflozin (EMPA)
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will start with 10 mg dose, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 25 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food.
Trial: NCT06731023
Drug: Bismuth
RxNorm normalized name: Bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth 0.6g bid
Trial: NCT06731023
Drug: Vonoprazan
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: vonoprazan 20mg bid
Trial: NCT06731023
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1g bid
Trial: NCT06731023
Drug: Rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin 0.15g bid
Trial: NCT06731023
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 400mg qid
Trial: NCT06730373
Drug: Disitamab Vedotin
RxNorm normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg IV every 3 weeks
Trial: NCT06730373
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg IV every 3 weeks
Trial: NCT06730373
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 40-60 mg BID for 14 days, every 3 weeks
Trial: NCT06730373
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: First load dose is 8.0mg/kg , then 6.0 mg/kg IV every 3 weeks
Trial: NCT06730373
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m2 Q3W
Trial: NCT06730373
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg/m²
Trial: NCT06730373
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg/m²
Trial: NCT06716216
Drug: Drug: Semaglutide Administered SC
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Active Comparator: 1 mg Semaglutide~1 mg semaglutide administered SC once a week
Trial: NCT06716606
Drug: Belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab will be administered.
Trial: NCT00000179
Drug: Trazodone
RxNorm normalized name: Trazodone
DrugBank: Trazodone (DB00656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000179
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06725732
Drug: Tranexamic Acid (TXA)
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To see if nebulised TXA is better to control blood loss in functional Endoscopic sinus surgery
Trial: NCT06725732
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To see if intravenous TXA is better to control blood loss in functional Endoscopic sinus surgery
Trial: NCT06726395
Drug: Penicillin G_1200mg
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: benzylpenicillin preferred dosing 1gx4
Trial: NCT06726395
Drug: cloxacillin
RxNorm normalized name: Cloxacillin
DrugBank: Cloxacillin (DB01147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cloxacillin 2gx4
Trial: NCT06705764
Drug: Tezepelumab
RxNorm normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg (1.91 ml) subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.~Open-label extension study from Day 90 to Day 180 with Tezepelumab dosing at Day 90
Trial: NCT06705595
Drug: Lidocaine Spray on DLT
RxNorm normalized name: lidocaine Mucosal Spray
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before intubation, participants will receive 10% lidocaine spray applied to the distal surface and cuffs of the double-lumen tube (DLT).
Trial: NCT06705595
Drug: Saline (Placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before intubation, participants will receive 1 ml of 0.9% saline applied to the distal surface and cuffs of the double-lumen tube (DLT).
Trial: NCT06733038
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 840 mg iv over 30 minutes (60 minutes at first infusion) day 1
Trial: NCT06733038
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg iv over 90 minutes at cycle 1 (if well tolerated, it is administered over 60 minutes at cycle 2, and over 30 minutes at cycle 3) day 1
Trial: NCT06733038
Drug: Irinotecan (CPT-11)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 165 mg/sqm iv over 60 minutes day 1
Trial: NCT06733038
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/sqm iv over 2 hours day 1
Trial: NCT05554341
Drug: Nilotinib Hydrochloride Monohydrate
RxNorm normalized name: NILOTINIB HYDROCHLORIDE MONOHYDRATE
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05554341
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT06209281
Drug: Low dose atropine sulfate eye drops
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer to eyes
Trial: NCT06736717
Drug: Onvansertib
RxNorm normalized name: Onvansertib
DrugBank: Onvansertib (DB15110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 or30mg flat dose - depending on results from safety lead-in. Administered concurrently with NALIRIFOX.~Once daily on D1-5 of each 14-day cycle.
Trial: NCT06737341
Drug: Bupivacaine Liposomes(BL)
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20ml of bupivacaine liposomes (266mg) + 10 ml of bupivacaine 0.75% hydrochloride + 20ml saline for ultrasound guided CMB.
Trial: NCT06737341
Drug: Bupivacaine(B)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.75% bupivacaine hydrochloride + 40ml normal saline for ultrasound-guided bilateral costal margin block
Trial: NCT06737042
Drug: GZR18
RxNorm normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GLP-1
Trial: NCT06737042
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT06737081
Drug: SAL-0951 tablets 4mg
RxNorm normalized name: Magnesium Salicylate Tablets
DrugBank: Magnesium salicylate (DB01397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Trial: NCT06737081
Drug: SAL-0951 tablets 5mg
RxNorm normalized name: Magnesium Salicylate Tablets
DrugBank: Magnesium salicylate (DB01397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: initial phase：5mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Trial: NCT06738979
Drug: TQF3510 (Semaglutide Injection)
RxNorm normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide injection is a long-acting Glucagon-like peptide-1 (GLP-1) receptor agonist.